MASH resolution without worsening of fibrosis: 2.4 mg dose: 47% of participants (vs 14% placebo) 4.8 mg dose: 62% of participants (vs 14% placebo) 6.0 mg dose: 43% of participants (vs 14% placebo) Liver fat reduction of at least 30%: 2.4 mg dose: 63% of participants 4.8 mg dose: 67% of participants 6.0 mg dose: 57% of participants Placebo: 14% of participants Fibrosis improvement by at least one stage: Survodutide groups: 34-36% Placebo: 22% The percentage change from baseline in liver fat content after 48 weeks was a staggering 62% reduction in the 6.0 mg group, compared to just 5.7% in the placebo group
Curr DiabRep 20:19 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G (2021) Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials
Rybelsus and Others Rybelsus is the first oral GLP-1 drug, offering an option for those who dont want injections
Direct Meds Team Every body is different, but most of our patients report reduced cravings and more control over food within the first 24 weeks
Are there any side effects of weight loss drugs
However, more severe side effects, such as pancreatitis and kidney problems, can occur